Basic & Clinical Pharmacology & Toxicology最新文献

{"title":"Models of Endocrine-Disrupting Effects: Human Placental Steroidogenesis","authors":"Line Mathiesen,&nbsp;Dea Sandal,&nbsp;Ida Elise Moelgaard Hammer,&nbsp;Bjarne Styrishave,&nbsp;Lisbeth E. Knudsen","doi":"10.1111/bcpt.70073","DOIUrl":"https://doi.org/10.1111/bcpt.70073","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Endocrine disruption during pregnancy has gained increasing interest as epidemiological studies report associations of exposures and adverse effects on fetal growth, followed by effects on the growing child and ultimately in the adult. When studying endocrine disruption during pregnancy, the placental steroidogenesis is difficult to model, as the human placenta is unique in the pathway of cellular uptake of cholesterol, the high levels of progesterone production and the expression of aromatase. Models to test for endocrine disruption should respect species differences, with preference to human models for human risk assessment. Here, we present existing research of placental steroidogenesis and other placental hormones using human placental models: placental perfusion, placental explants, fragments, microsomes and vesicles, primary cell culture, stem cells, placenta on a chip and choriocarcinoma cell cultures: BeWo, HTR-8/SVneo, Jar, JEG-3 and ACH-3P. We conclude that there is a lack of research focused on placental steroidogenesis and the effects of endocrine-disrupting compounds. Advantages and limitations of existing models are discussed, and future directions suggested.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144598271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comprehensive Narrative Review of Protonitazene: Pharmacological Characteristics, Detection Techniques, and Toxicology","authors":"Jake Verbeek,&nbsp;David J. Brinkman","doi":"10.1111/bcpt.70078","DOIUrl":"https://doi.org/10.1111/bcpt.70078","url":null,"abstract":"<p>Protonitazene (PNZ) is a synthetic opioid emerging in Europe, Australia, North America and South America with a rapidly increasing number of intoxications. To describe PNZ's pharmacological characteristics, detection methods and the clinical presentation and management of PNZ intoxications, the PubMed database was searched for original articles in English concerning PNZ in any way. All articles were read and analysed completely for their suitability for inclusion, based on the article type, integrity and its description of PNZ pharmacology, toxicology and PNZ intoxications. Of the 21 articles resulting from the search, 16 articles were included. PNZ is a μ-opioid receptor agonist that induces opioid-like effects at subnanomolar concentrations at a much higher potency than morphine and fentanyl. 4′-Hydroxy-nitazene is a shared metabolite of most nitazenes and can be detected in urine for longer than most nitazenes, providing a way to detect nitazenes without knowing the parent nitazene. PNZ is detectable in whole blood, urine, bile, gastric contents and hair using several forms of mass spectrometry at subnanomolar concentrations but is not detectable in urine using traditional opioid test strips. More reports about monointoxications of PNZ and an appropriate public health response are necessary.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144581987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary Microvascular Dysfunction in Ischaemic Heart Disease: Lessons From Large Animal Models","authors":"Oana Sorop,&nbsp;J. van de Wouw,&nbsp;Daphne Merkus,&nbsp;Dirk J. Duncker","doi":"10.1111/bcpt.70074","DOIUrl":"https://doi.org/10.1111/bcpt.70074","url":null,"abstract":"<p>The coronary microvasculature is principally responsible for matching coronary blood flow to myocardial demand of oxygen and nutrients. Short-term control of coronary blood flow is achieved via alterations in coronary microvascular tone, whereas long-term control of coronary flow also involves remodelling of the coronary microvasculature, including adjustments in vascular structure, diameter and density. In the past 50 years, considerable research efforts have been directed at understanding the functional and structural coronary microvascular adaptations involved in matching myocardial oxygen supply to demand, and how these mechanisms are affected by various diseases. In this review article, we will discuss our current understanding of the mechanisms underlying the regulation of coronary microvascular tone under healthy physiological conditions and in ischaemic heart disease. We will specifically discuss the role of microvascular dysfunction in obstructive and non-obstructive coronary artery disease, as studied in large animal models and confirmed in human studies. Future research should be directed at further unravelling the disease-specific mechanisms of coronary microvascular dysfunction in order to identify therapeutic targets to improve microvascular function in patients with ischaemic heart disease.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70074","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144581986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Potentially Inappropriate Medications Identified by STOPPFrail Among Danish Care Home Residents: A Nationwide Drug Utilisation Study","authors":"Katrine Mose,&nbsp;Carina Lundby,&nbsp;Martin Thomsen Ernst,&nbsp;Jesper Ryg,&nbsp;Anton Pottegård,&nbsp;Lotte Rasmussen","doi":"10.1111/bcpt.70076","DOIUrl":"https://doi.org/10.1111/bcpt.70076","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Care home residents represent a frail population with limited life expectancy and are often prescribed multiple medications. As therapeutic goals shift in this population, certain treatments may become inappropriate. This study aims to describe potentially inappropriate medication use among Danish care home residents using the Screening Tool of Older Persons Prescriptions in Frail adults with limited life expectancy (STOPPFrail) in a nationwide cohort of all Danish care home residents admitted 2015–2023, focusing on the time around admission and the last year of life. The cohort comprised 129 635 residents (61% women, median age 84 years). Around admission, 88% used at least one STOPPFrail medication, most commonly antihypertensives (58% before, 55% after), lipid-lowering therapies (31%, 27%) and proton-pump inhibitors (30%, 30%). The rate of new use increased from 2.6/100 residents/month 2 years before admission, peaking at 9.6/100 residents/month 2 months prior. Hospital physician prescribing increased as care home admission approached, after which general practitioners prescribed most prescriptions. Over 90% used at least one STOPPFrail medication during the last year of life, with increases in proton-pump inhibitors and antipsychotics, the latter most frequently initiated in the last 4 months. These findings underscore the importance of regular assessment and targeted efforts to improve prescribing appropriateness.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A New Method for Antispastic Effect in Coronary Artery Bypass Grafts by Using a L- and T-Type Calcium Channel Blocker Efonidipine","authors":"Xiu-Yun Yin,&nbsp;Hai-Tao Hou,&nbsp;Ming-Rui Li,&nbsp;Qin Yang,&nbsp;Guo-Wei He","doi":"10.1111/bcpt.70077","DOIUrl":"https://doi.org/10.1111/bcpt.70077","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Internal mammary artery (IMA) is the most commonly used graft in coronary artery bypass grafting (CABG). Spasm of the IMA is a long-recognized problem with the reported prevalence of 0.43% in all CABG surgery. This study explored the antispastic effect and the mechanism of a new generation of dihydropyridine calcium channel blocker efondipine in the IMA.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Discarded distal IMA taken from 54 patients undergoing CABG were collected. The concentration–relaxation curves of efonidipine (−12 to −4.5 log M) in the IMA precontracted with KCl or U46619 were constructed, and the effect was compared to a T-type calcium channel blocker, mibefradil. The pretreatment effect of efonidipine on the contraction of vasoconstrictors was also studied. The Cav1.2 and Cav3.1 protein expression was detected by Western blot.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Efonidipine-induced dose-dependent relaxation in the IMA precontracted with KCl or U46619 (<i>p</i> &lt; 0.05). Pretreatment with −6.5 log M of efonidipine significantly inhibited the vasoconstriction by KCl (<i>p</i> &lt; 0.01) or U46619 (<i>p</i> = 0.04). Cav1.2 and Cav3.1 protein expression levels were significantly decreased by efonidipine. The relaxation effect of efonidipine was significantly greater than that of mibefradil.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The present study revealed a significant antispastic effect of efonidipine in the human IMA due to its effect on the expression of L-type (Cav1.2) and T-type (Cav3.1) proteins. The dual effect of efonidipine on both L- and T-type calcium channels is significantly greater than that of T-type calcium channel blockers. These findings suggest that efonidipine is an effective drug to prevent and treat vasospasm of the IMA during CABG surgery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144573449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in mRNA Expression of Selected Cytochrome P450, Transporters and Nuclear Receptors Among Various Rat Models of Metabolic Syndrome","authors":"Jan Soukop,&nbsp;Zuzana Rácová,&nbsp;Ludmila Kazdová,&nbsp;Iveta Zapletalová,&nbsp;Martin Poruba,&nbsp;Hana Malínská,&nbsp;Martina Hüttl,&nbsp;Irena Marková,&nbsp;Kristýna Nováková,&nbsp;Rostislav Večeřa","doi":"10.1111/bcpt.70075","DOIUrl":"https://doi.org/10.1111/bcpt.70075","url":null,"abstract":"<p>Metabolic syndrome (MetS) is a cluster of risk factors that increase the likelihood of developing cardiovascular, metabolic and other diseases. The pharmacological management of MetS often involves polypharmacy, making it essential to understand how drug-metabolising enzymes, transporters, transcription factors and other proteins involved are affected under different metabolic conditions. This study investigated the relative mRNA expression of key hepatic and intestinal genes involved in drug metabolism, including <i>Cyp1a2</i>, <i>Cyp3a23</i>, <i>Cyp2d1</i>, <i>Cyp2c11</i>, <i>Cyp2c6</i>, <i>Cyp2e1</i>, <i>Cyp7a1</i>, <i>Cyp2b1</i>, <i>Cyp2a1</i>, <i>Abcg5</i>, <i>Abcg8</i>, <i>Abcb1</i>, <i>Nr1i3</i>, <i>Nr1i2</i>, <i>Ahr</i>, <i>Gsta1</i> and <i>Comt</i>, in four nonobese rat models of MetS: hereditary hypertriglyceridaemic (HHTg), spontaneously hypertensive rat (SHR), SHR expressing transgenic human C-reactive protein (SHR-CRP), and bilaterally ovariectomised Wistar (W-OVX), compared to Wistar controls. Gene expression was quantified by RT–PCR with data normalised using the ^ΔΔCt method. Between the models studied, measurements showed significant differences in the liver. The upregulation of <i>Cyp2c6</i> and <i>Cyp3a23</i> was observed only in SHR; upregulated <i>Cyp2d1</i> was found in SHR as well as in HHTg rats. The downregulated <i>Cyp1a2</i> was measured in a condition of hypertriglyceridemia, postmenopause or hypertension. These findings highlight model-specific alterations in gene expression that may affect drug metabolism and interactions. The HHTg may be, in particular, a suitable model for preclinical studies focusing on intestinal drug–drug interactions in MetS-related conditions.</p>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144558085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Review of the Delay of Chronic Kidney Disease Progression by Wuling San on Improving Renal Fibrosis","authors":"Zhijun Zeng,&nbsp;Beini Lao,&nbsp;Ke Liu,&nbsp;Yiwen Cao,&nbsp;Yongan Liao,&nbsp;Jiuyao Zhou","doi":"10.1111/bcpt.70071","DOIUrl":"https://doi.org/10.1111/bcpt.70071","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Renal fibrosis is a common pathological process in chronic kidney disease (CKD), which is mainly characterized by glomerulosclerosis and tubulointerstitial fibrosis. The formation and development of renal fibrosis are stimulated by pro-inflammatory as well as pro-fibrosis factors released by inflammatory cells. Wuling San is an ancient Chinese classical formula for urination-promoting and dampness-draining, which can regulate the metabolism of water and fluid and has exerted therapeutic effects on various chronic kidney diseases by reducing oedema, inflammation, and improving glomerulosclerosis and renal interstitial fibrosis. However, further study is still needed to explore the mechanism. Based on the research analysis with the help of CiteSpace, the following three directions were the possible mechanisms in improving renal fibrosis: inhibiting the conversion of renal cells to myofibroblasts; regulating amino acid, lipid and energy metabolism and reducing extracellular matrix (ECM) deposition; and regulating the RhoA/ROCK pathway, the downstream of G protein-coupled receptor (GPCR). This review aims to summarize the mechanism of action of Wuling San in the treatment of CKD from the perspective of antifibrosis, which can help to explore the new ideas and directions of Wuling San in the treatment of renal diseases.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 2","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144515085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limited Sampling Strategies to Predict Mycophenolic Acid and Tacrolimus Area Under the Concentration–Time Curve in Steroid-Free Kidney Transplant Patients","authors":"Katrine Agergaard,&nbsp;Helle C. Thiesson,&nbsp;Jan Carstens,&nbsp;Christine E. Staatz,&nbsp;Erkka Järvinen,&nbsp;Flemming Nielsen,&nbsp;Heidi Dahl Christensen,&nbsp;Rikke Juul-Sandberg,&nbsp;Kim Brøsen,&nbsp;Tore Bjerregaard Stage,&nbsp;Maria C. Kjellsson,&nbsp;Troels K. Bergmann","doi":"10.1111/bcpt.70056","DOIUrl":"https://doi.org/10.1111/bcpt.70056","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>This study aimed to develop limited sampling strategies to predict oral mycophenolic acid (MPA) exposure from one to three blood samples in stable steroid-free kidney-transplanted patients and assess if the same scheme could predict tacrolimus exposure. Additionally, we aimed to validate existing strategies, and to describe the pharmacokinetics of MPA and its inactive metabolite, MPA-glucuronide (MPAG), in our cohort. We analysed data from dense pharmacokinetic sampling from 15 steroid-free kidney-transplanted patients, which were prospectively enrolled as part of larger cohort. Drug concentration was analysed in plasma (MPA, MPAG) or in whole blood (tacrolimus) using LC–MS. Exposure (AUC_0-12h) was based on non-compartmental analysis (MPA, MPAG) or model-derived (tacrolimus). Limited sampling strategies were developed using multiple stepwise linear regression analysis and evaluated for bias and imprecision and using Bland–Altman analysis. Median AUC_0-12h was 31.2 μg/mL·h, 346.6 μg/mL·h and 81.9 ng/mL·h for MPA, MPAG and tacrolimus, respectively. Limited sampling strategies incorporating measurements at C₀ and C_1.5, or at C₀, C_0.5 and C_1.5 could predict MPA and tacrolimus AUC_0-12h with low (&lt; 15%) bias and imprecision. None of the previous strategies could adequately predict MPA AUC_0-12h. Limited sampling strategies for MPA and tacrolimus can potentially replace full pharmacokinetic profiling in steroid-free kidney transplant patients. External validation is needed before implementation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Summary</h3>\u0000 \u0000 <p>Kidney-transplanted patients are treated with immunosuppressive drugs throughout the lifespan of the transplanted organ. In this study, we aimed to derive mathematical equations that can simultaneously predict the total oral drug exposure of two of these drugs (tacrolimus and mycophenolate mofetil) based on few blood samples. We analysed drug concentration in blood samples from 15 patients, calculated their exposure and assessed how accurately the mathematical equations could predict the exposure. We could predict the total drug exposure from two or three samples, and these equations can be used in future research and in the clinic to ensure proper immunosuppressive levels.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70056","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144367553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"p-Cresol and p-Cresyl Sulphate Boost Oxidative Stress: A Systematic Review of Recent Evidence","authors":"Rinvil Renaldi,&nbsp;Tjhin Wiguna,&nbsp;Antonio M. Persico,&nbsp;Andi Jayalangkara Tanra","doi":"10.1111/bcpt.70065","DOIUrl":"https://doi.org/10.1111/bcpt.70065","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Recent studies have emphasized the significant role of p-cresol and its conjugated form, p-cresyl sulphate (PCS), in enhancing oxidative stress, leading to potential detrimental effects on various biological systems. Both p-cresol and PCS contribute to increased production of reactive oxygen species (ROS), which can result in tissue damage, inflammation and a cascade of physiological abnormalities. Elevated p-cresol levels have been associated with greater clinical severity in autism spectrum disorder, correlating with more severe behavioural manifestations and a history of regression. This systematic review explores the recent evidence on how these compounds promote oxidative stress and their impact on different health conditions. This review also addresses the involvement of p-cresol and PCS in conditions such as chronic kidney disease, Parkinson's disease and other neurodegenerative disorders, where oxidative damage contributes to disease progression. Furthermore, this review highlights the need for further research to understand the precise mechanisms by which p-cresol and PCS modulate oxidative stress and their potential as biomarkers for clinical diagnosis and disease management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Summary</h3>\u0000 \u0000 <div>\u0000 \u0000 <ul>\u0000 \u0000 \u0000 <li>This focused review systematically summarizes recent evidence that oxidative stress plays an important role in the damage of biological systems produced by two uremic toxins, p-cresol and its conjugated form, p-cresyl sulphate (PCS).</li>\u0000 \u0000 \u0000 <li>p-cresol coming from environmental sources or produced by some gut bacterial strains, modulates various conditions, like chronic kidney disease, Parkinson's disease and autism spectrum disorder, among others.</li>\u0000 \u0000 \u0000 <li>Oxidative damage and inflammation seemingly contribute to disease onset, progression and/or severity.</li>\u0000 \u0000 \u0000 <li>The exact mechanism by which p-cresol and PCS promote oxidative stress, their influence on disease trajectory and their potential role as biomarkers merit further investigation.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"‘This Is My Decision’: A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss","authors":"Trine Graabæk,&nbsp;Nini Thi Nguyen,&nbsp;Malene Svoldgaard Sørensen,&nbsp;Carina Lundby","doi":"10.1111/bcpt.70069","DOIUrl":"https://doi.org/10.1111/bcpt.70069","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <p>Individuals using semaglutide for weight loss constitute a new, sizeable patient group, yet limited qualitative research of this group exists. Therefore, we explored their perspectives, including motivation for treatment, attitudes towards the medication and experiences with its use. Semistructured interviews with seven individuals (five women, average age 50 years, average treatment duration 9 months) were conducted, audio-recorded, transcribed verbatim and analysed using systematic text condensation. We identified three themes: ‘I have absolutely run out of options’, ‘I am lucky to have a cooperative doctor’ and ‘It's the feeling of being normal’. Using semaglutide for weight loss was considered a life-changing event, as most respondents were concerned about declining physical health due to overweight. Most showed strong autonomy in managing their treatment, including delaying dose increases, reducing the dose or taking individual doses by ‘counting clicks’. Our data suggest a need for more support from healthcare professionals to guide individuals using semaglutide for weight loss, particularly in dosing, monitoring and managing side effects, with an emphasis on individualized and holistic care. Further research on individuals' perspectives related to weight loss and semaglutide use is needed to maintain and improve individuals' quality of life.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Summary</h3>\u0000 \u0000 <div>\u0000 \u0000 <ul>\u0000 \u0000 \u0000 <li>More people are using semaglutide to lose weight, but we still know little about their experiences.</li>\u0000 \u0000 \u0000 <li>To learn more, we interviewed seven users.</li>\u0000 \u0000 \u0000 <li>Many saw the treatment as life-changing, having struggled with overweight and concerns about their health.</li>\u0000 \u0000 \u0000 <li>It was important to them to manage the dose themselves.</li>\u0000 \u0000 \u0000 <li>Some delayed increasing the dose or took less than recommended by ‘counting clicks’.</li>\u0000 \u0000 \u0000 <li>Our findings show that people using semaglutide for weight loss need more support from healthcare professionals—especially with dosing, side effects and personal guidance.</li>\u0000 \u0000 \u0000 <li>More research is needed to better support these users and improve their quality of life.</li>\u0000 </ul>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":8733,"journal":{"name":"Basic & Clinical Pharmacology & Toxicology","volume":"137 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bcpt.70069","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144292616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}